+

US6511827B1 - Nucleotide encoding human galanin receptor 3 (GALR3) - Google Patents

Nucleotide encoding human galanin receptor 3 (GALR3) Download PDF

Info

Publication number
US6511827B1
US6511827B1 US09/595,549 US59554900A US6511827B1 US 6511827 B1 US6511827 B1 US 6511827B1 US 59554900 A US59554900 A US 59554900A US 6511827 B1 US6511827 B1 US 6511827B1
Authority
US
United States
Prior art keywords
leu
ala
val
ser
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/595,549
Other languages
English (en)
Inventor
Andrew D. Howard
Margaret A. Cascieri
Roy G. Smith
Kathleen A. Sullivan
Carina Tan
Leonardus H. T. Van Der Ploeg
Kevin R. Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
University of Virginia UVA
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US09/595,549 priority Critical patent/US6511827B1/en
Assigned to MERCK & CO., INC. reassignment MERCK & CO., INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOWARD, ANDREW D., SMITH, ROY G., CASCIERI, MARGARET A., SULLIVAN, KATHLEEN A., TAN, CARINA, VAN DER PLOEG, LEONARDOUS H.T.
Assigned to VIRGINIA, UNIVERSITY OF reassignment VIRGINIA, UNIVERSITY OF ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LYNCH, KEVIN R.
Priority to US10/212,980 priority patent/US20030023074A1/en
Application granted granted Critical
Publication of US6511827B1 publication Critical patent/US6511827B1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: MERCK & CO., INC.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a novel galanin receptor, designated GALR3, to nucleotides encoding same, and to assays making use thereof.
  • galanin Although first isolated from porcine intestine, galanin is widely distributed in the central and peripheral nervous system. Galanin in most species is a 29 amino acid peptide with an amidated carboxyl terminus. Human galanin is unique in that it is longer, 30 amino acids, and is not amidated. There is strong conservation of the galanin sequence with the amino terminal fifteen residues being absolutely conserved in all species. Galanin immunoreactivity and binding is abundant in the hypothalamus, the locus coeruleus, the hippocampus and the anterior pituitary, as well as regions of the spinal cord, the pancreas and the gastrointestinal tract.
  • galanin antisense oligonucleotides when injected into the PVN produce a specific decrease in galanin expression associated with a decrease in fat ingestion and total caloric intake while hardly affecting either protein or carbohydrate intake.
  • galanin appears to be one potential neurochemical marker related to the behavior of fat ingestion.
  • Galanin inhibits cholinergic function and impairs working memory in rats. Lesions that destroy cholinergic neurons result in deficits in spatial learning tasks. While locally administered acetylcholine (ACh) reverses some of this deficit, galanin blocks this ACh-mediated improvement.
  • ACh acetylcholine
  • galanin antagonists may be therapeutically useful in alleviating cognitive impairment.
  • Galanin levels are particularly high in dorsal root ganglia. Sciatic nerve resection dramatically up-regulates galanin peptide and mRNA levels. Chronic administration of galanin receptor antagonists (M35, M15) after axotomy results in a marked increase in self mutilation behavior in rats, generally considered to be a response to pain. Application of antisense oligonucleotides specific for galanin to the proximal end of a transected sciatic nerve suppressed the increase in galanin peptide levels with a parallel increase in autotomy.
  • Galanin injected intrathecally acts synergistically with morphine to produce analgesia, this antinociceptive effect of morphine is blocked by galanin receptor antagonists.
  • galanin agonists may have some utility in relieving neural pain.
  • galanin The actions of galanin are mediated by high affinity galanin receptors that are coupled by pertussis toxin sensitive G i /G o proteins to inhibition of adenylate cyclase activity, closure of L-type Ca ++ channels and opening of ATP-sensitive K + channels.
  • Specific binding of 125 I-galanin (Kd approximately 1 nM) has been demonstrated in areas paralleling localization of galanin immunoreactivity: hypothalamus, ventral hippocampus, basal forebrain, spinal cord, pancreas and pituitary. In most tissues the amino terminus (GAL 1-15) is sufficient for high affinity binding and agonist activity.
  • Gal(1-16) is at least 1000 times more active than pGAL(3-29) as an inhibitor of 125 I-porcine galanin binding to this receptor transiently expressed in COS cells. It remains to be determined whether this receptor subtype represents the hypothalamic receptor that mediates the galanin specific feeding behavior.
  • This invention relates to a novel galanin receptor, designated GALR3, substantially free from associated proteins, and to GALR3-like receptors which are at least about 40% homologous and which have substantially the same biological activity.
  • the GALR3-like receptors are at least about 60%, and more preferably at least about 75%, and even more preferably at least about 85% homologous to a GALR3 receptor.
  • This invention also relates specifically to rat, human and mouse GALR3, substantially free from associated proteins, and to receptors which are at least about 50% homologous and which have substantially the same biological activity.
  • Another aspect of this invention are primate and non-primate GALR3 proteins which are encoded by substantially the same nucleic acid sequences, but which have undergone changes in splicing or other RNA processing-derived modifications or mutagenesis-induced changes, so that the expressed protein has a homologous, but different amino acid sequence from the native forms.
  • These variant forms may have different and/or additional functions in human and animal physiology or in vitro in cell based assays.
  • a further aspect of this invention are nucleic acids which encode a GALR3 receptor, a GALR3-like receptor or a functional equivalent of a GALR3 receptor from rat, human, mouse, swine, or other species. These nucleic acids may be free from associated nucleic acids, or they may be isolated or purified.
  • the nucleic acids which encode a receptor of this invention may be any type of nucleic acid. Preferred forms are DNAs, including genomic and cDNA, although this invention specifically includes RNAs as well. Nucleic acid constructs may also contain regions which control transcription and translation such as one or more promoter regions, termination regions, and if desired enhancer regions.
  • the nucleic acids may be inserted into any known vector including plasmids, and used to transfect suitable host cells using techniques generally available to one of ordinary skill in the art.
  • Another aspect of this invention are vectors comprising nucleic acids which encode GALR3, and host cells which contain these vectors. Still another aspect of this invention is a method of making GALR3 comprising introducing a vector comprising nucleic acids encoding GALR3 into a host cell under culturing conditions.
  • Yet another aspect of this invention are assays for GALR3 ligands which utilize the receptors and/or nucleic acids of this invention.
  • Preferred assays of this embodiment compare the binding of the putative GALR3 ligand to the binding of galanin to GALR3.
  • FIG. 1 is the DNA sequence of human GALR3 gene, clone GALR3—3 (SEQ ID NO:1).
  • FIG. 2 is the deduced amino acid sequence of human GALR3, clone GALR3—3 (SEQ ID NO:2).
  • FIG. 3 is the DNA sequence (open reading frame only) of human GALR3, clone GALR3-2 (SEQ ID NO:3).
  • FIG. 4 is the deduced amino acid sequence of GALR3, clone GALR3-2 (SEQ ID NO:4)
  • FIG. 5 is a comparison of the open reading frame protein sequences of human and rat GALR3 with the corresponding sequences of GALR1 (mouse—SEQ ID NO:5, rat—SEQ ID NO:6, and human—SEQ ID NO:7) and GALR2 (mouse—SEQ ID NO:8, rat—SEQ ID NO:9, and human—SEQ ID NO:10).
  • FIG. 6 is a phylogenetic analysis of the putative GALR3 protein sequence.
  • FIG. 7 illustrates the competition curves for 125 I-porcine glanin against human and porcine galanin.
  • FIG. 8 is the DNA sequence of rat GALR3 from region TM4 to region TM7 (SEQ ID NO:11).
  • FIG. 9 is the deduced amino acid sequence of rat GALR3 from region TM4 to region TM7 (SEQ ID NO:12).
  • Substantially free from associated proteins means that the receptor is at least about 90%, and preferably at least about 95% free from other cell membrane proteins which are normally found in a living mammalian cell which expresses a galanin receptor.
  • “Substantially free from associated nucleic acids” means that the nucleic acid is at least about 90%, and preferably at least about 95%, free from other nucleic acids which are normally found in a living mammalian cell which naturally expresses a galanin receptor gene.
  • Substantially the same biological activity means that the receptor-galanin binding constant is within 5-fold of the binding constant of GALR3 and galanin, and preferably within 2-fold of the binding constant of GALR3 and galanin.
  • “Stringent post-hybridizational washing conditions” means 0.1 ⁇ standard saline citrate (SSC) at 65° C.
  • Standard post-hybridizational washing conditions means 6 ⁇ SSC at 55° C.
  • Relaxed post-hybridizational washing conditions means 6 ⁇ SSC at 30° C., or 1 to 2 ⁇ SSC at 55° C.
  • “Functional equivalent” means that a receptor which does not have the exact same amino acid sequence of a naturally occurring GALR3 protein due to alternative splicing, deletions, mutations, or additions, but retains at least 1%, preferably 10%, and more preferably 25% of the biological activity of the naturally occurring receptor. Such derivatives will have a significant homology with a natural GALR3 and can be detected by reduced stringency hybridization with a DNA sequence obtained from a GALR3.
  • the nucleic acid encoding a functional equivalent has at least about 60% homology at the nucleotide level to a naturally occurring receptor nucleic acid.
  • GALR3 a third galanin receptor
  • the human (clone 3—3 and 3-2) and rat GALR3 sequences are given in FIGS. 1, 3 and 8 , respectively, and are referenced in the Examples; however it is to be understood that this invention specifically includes GALR3 without regard to the species and, in particular, specifically includes rodent (including rat and mouse), rhesus, swine, chicken, cow and human.
  • the galanin 3 receptors are highly conserved throughout species, and one of ordinary skill in the art, given the rat, human and/or mouse sequences presented herein, can easily design probes to obtain the GALR3 from other species.
  • GALR3 proteins contain various functional domains, including one or more domains which anchor the receptor in the cell membrane, and at least one ligand binding domain. As with many receptor proteins, it is possible to modify many of the amino acids, particularly those which are not found in the ligand binding domain, and still retain at least a percentage of the biological activity of the original receptor. Thus this invention specifically includes modified functionally equivalent GALR3s which have deleted, truncated, or mutated N-terminal portions. This invention also specifically includes modified functionally equivalent GALR3s which contain modifications and/or deletions in other domains, which are not accompanied by a loss of functional activity.
  • the proteins of this invention were found to have structural features which are typical of the 7-transmembrane domain (TM) containing G-protein linked receptor superfamily (GPC-R's or 7-TM receptors).
  • TM 7-transmembrane domain
  • GPC-R's or 7-TM receptors 7-transmembrane domains
  • the intact GALR3 of this invention was found to have the general features of GPC-R's, including seven transmembrane regions, three intra- and extracellular loops, and the GPC-R protein signature sequence.
  • the TM domains and GPC-R protein signature sequence are noted in the protein sequences of the GALR3. Not all regions are required for functioning, and therefore this invention also comprises functional receptors which lack one or more non-essential domains.
  • the DNA sequence encoding the putative GALR3 is shown in FIGS. 1 and 3.
  • the human putative GALR3 gene is organized similarly to human GALR2 with a single intron ( ⁇ 1 kb) dividing the open reading into two exons with Exon 1 consisting of ⁇ 350 bp, and Exon 2 ⁇ 700 bp.
  • the open reading frame protein sequence for this novel gene (FIGS. 2 and 4) is most closely related to GALR2 and GALR1 with 58, 75% identity and similarity to human GALR2, and 37, 61% identity and similarity to rat GALR1 (FIG. 5 ).
  • the human GALR3 protein bears strong sequence identity and similarity to the rat GALR3 ortholog.
  • This invention also relates to truncated forms of GALR3, particularly those which encompass the extracellular portion of the receptor, but lack the intracellular signaling portion of the receptor, and to nucleic acids encoding these truncated forms.
  • Such truncated receptors are useful in various binding assays.
  • this invention specifically includes modified functionally equivalent GALR3s which have deleted, truncated, or mutated N-terminal portions.
  • This invention also specifically includes modified functionally equivalent GALR3s including receptor chimeras which contain modifications and/or deletions in other domains, which are not accompanied by a loss of functional activity.
  • Assays which make up further aspects of this invention include binding assays (competition for 125 I-galanin binding), coupling assays (including galanin-mediated inhibition of forskolin-stimulated adenylate cyclase in cells expressing galanin receptors), measurement of galanin-stimulated calcium release in cells expressing galanin receptors (such as aequorin assays), stimulation of inward rectifying potassium channels (GIRK channels, measured by voltage changes) in cells expressing galanin receptors, and measurement of pH changes upon galanin stimulation of cells expressing galanin receptors as measured with a microphysiometer.
  • binding assays consistition for 125 I-galanin binding
  • coupling assays including galanin-mediated inhibition of forskolin-stimulated adenylate cyclase in cells expressing galanin receptors
  • measurement of galanin-stimulated calcium release in cells expressing galanin receptors such as aequorin assays
  • Host cells may be cultured under suitable conditions to produce GALR3.
  • An expression vector containing DNA encoding the receptor may be used for expression of receptor in a recombinant host cell.
  • Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as E. coli, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to Drosophila, Spodoptera, and silkworm derived cell lines.
  • L cells L-M(TK ⁇ ) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).
  • the specificity of binding of compounds showing affinity for the receptor is shown by measuring the affinity of the compounds for cells transfected with the cloned receptor or for membranes from these cells. Expression of the cloned receptor and screening for compounds that inhibit the binding of radiolabeled ligand to these cells provides a rational way for rapid selection of compounds with high affinity for the receptor.
  • These compounds identified by the above assays may be agonists or antagonists of the receptor and may be peptides, proteins, or non-proteinaceous organic molecules.
  • functional assays of the receptor may be used to screen for compounds which affect the activity of the receptor. Such functional assays range from ex vivo muscle contraction assays to assays which determine second messenger levels in cells expressing the receptor.
  • the second messenger assays include, but are not limited to, assays to measure cyclic AMP or calcium levels or assays to measure adenyl cyclase activity. These compounds identified by the above assays may be agonists, antagonists, suppressors, or inducers of the receptor. The functional activity of these compounds is best assessed by using the receptor either natively expressed in tissues or cloned and exogenously expressed.
  • galanin agonists and antagonists may be identified.
  • a galanin agonist is a compound which binds to the GALR3, such as a galanin mimetic, and produces a cellular response which is at least about equivalent to that of galanin, and which may be greater than that of galanin. Such compounds would be useful in situations where galanin insufficiency causes anorexia, or for treatment of pain.
  • galanin antagonists may be identified.
  • a galanin antagonist is a compound which can bind to the GALR3, but produces a lesser response than that of native galanin. Such compounds would be useful in the treatment of obesity.
  • One assay of this invention is a method of identifying a compound which modulates GALR3 receptor comprising: a) culturing cells expressing the GALR3 receptor in the presence of the compound and b) measuring GALR3 receptor activity or second messenger activity. If desired, the determined activity can be compared to a standard, such as that measured using galanin as the compound. In preferred embodiments, the cells are transformed and express the GALR3 receptor.
  • the consultant cDNA clone (or shorter portions of, for instance, only 15 nucleotides long) may be used to probe libraries under hybridization conditions to find other receptors which are similar enough so that the nucleic acids can hybridize, and is particularly useful for screening libraries from other species.
  • hybridization conditions can vary from very stringent to relaxed. Proper temperature, salt concentrations, and buffers are well known.
  • GenBank National Center For Biotechnology Information, Bethesda, Md.
  • GenBank National Center For Biotechnology Information, Bethesda, Md.
  • the query algorithm is TFASTX and the output is placed in a file where alignments are sorted by query sequence and scored (cut-off based on the expectation value, set for example, at 0.01).
  • a DNA sequence alignment of 300 bp to a portion of a large BAC clone ( ⁇ 100,000 bp) with accession number Z97630 was identified from the high through-put genomic sequence (HTGS database, GenBank).
  • the complete open reading frame (ORF) for the putative gene encoding GALR3 was then identified using sequence from BAC Z97630 and an additional BAC clone, with assession number Z82241, from the HTGS database.
  • Genbank assession numbers corresponded to the following HTGS BAC clones (HS entries): Z97630, HS466N1; Z82241, HS8112.
  • PCR primers begining at the predicted initiating Met and ending more 3′ than the predicted stop codon were utilized to PCR from human genomic DNA a fragment containing the predicted Exon I, the intervening intron, and predicted Exon II. This PCR product was subcloned and sequenced, resulting in expression plasmid GALR3—3.
  • a human genomic DNA library (Stratagene, La Jolla, Calif.) was screened to isolate the putative GALR3 gene. Primary screening under medium stringency resulted in 6 positive plaques using an Exon 2 probe. One hybridizing phage plaque was obtained upon secondary screening. A 13 kb EcoR1/EcoRV fragment was identified from the genomic clone by Southern blotting, transferred into pBluescript vector (Stratagene, La Jolla, Calif.), and confirmed to be GALR3 by sequencing. A intronless GALR3 expression construct was assembled in a similar manner to that described above using Pfu DNA polymerase (Stratagene, La Jolla, Calif.) resulting in expression plasmid GALR3-2.
  • the human GalR3 cDNA expression construct was assembled stepwise from PCR products amplified from human genomic DNA. Each exon was PCR amplified using standard conditions.
  • the primers in for exon I were: Forward Exon I (5′-gcg aat tcg gta cca tgg ctg atg ccc aga aca t-3′; SEQ ID NO:13) and Reverse Exon I (5′-cgc ctg tcg aca gat aca gca gc -3′; SEQ ID NO:14).
  • the primers for exon II were: Forward Exon II (5′-tgt atc tgt cga cag gta acc tgg ccg tgc ggc acc c-3′; SEQ ID NO:15) and Reverse Exon II (5′-gcg cgg ccg ctt att ccg gtc ctc ggg c-3′; SEQ ID NO:16). PCR products were subcloned into pCRII and sequenced.
  • the putative GALR3 ORF was subcloned into pcDNA-1/amp (Invitrogen) resulting in plasmid GALR3—3; and pcDNA-3 (Invitrogen), resulting in plasmid GALR3-2.
  • GALR3 is expressed in numerous brain regions and peripheral tissues, as observed for GALR1 and GALR2.
  • COS-7 cells were transfected by electroporation.
  • COS-7 cells (1 ⁇ 10 7 ) were suspended in 0.85 ml of Ringers' buffer and 15 mg of the GALR3-2 or GALR3—3 expression plasmid was added to a 0.4 mm electroporation cuvette (Bio-Rad, Hercules, Calif.). Current was applied (960 mF, 260 V) using a Bio-Rad Electroporator device and the cells were transferred to a T-180 flask (Corning). Expression was allowed to proceed for 72 hrs.
  • Membranes were prepared from transfected cells following dissociation in enzyme-free dissociation solution (Specialty Media, Lavallette, N.J.) by disruption in a Dounce homogenizer in ice-cold membrane buffer (10 mM Tris, pH 7.4, 10 mM PMSF, 10 mM phosphoramidon, and 40 mg/ml bacitracin). After a low speed (1100 ⁇ g for 10 min. at 4° C.) and a high speed centrifugation (38,700 ⁇ g for 15 min. at 4° C.), membranes were resuspended in buffer and protein concentration determined (Bio-Rad assay kit).
  • Binding of 125 I-human or porcine galanin was measured in membranes using a buffer of 25 mM Tris pH 7.4, 0.5% BSA, 2 mM MgCl 2 , 40 ⁇ g/ml bacitracin, 4 mg/ml phosphoramidon, and 10 ⁇ M leupeptin in a total volume of 250 ml. 70 ⁇ M 125 I-human or porcine galanin was used.
  • Transfected cells expressing plasmid GALR3—3 were bound with 125 I-human galanin whereas cells expressing plasmid GALR3-2 were bound with 125 I-porcine galanin.
  • Primers based on the intronless human GALR3 sequence from TM4 and TM7 were designed and used to PCR amplify with Pfu DNA polymerase the rat GALR3 ortholog from rat genomic DNA.
  • a PCR product of the appropriate size (approximately 400 bp) that hybridized with an Exon 2 probe from the human GALR3 gene was subcloned into pBluescript vector (Stratagene, La Jolla, Calif.). The DNA sequence is shown is FIG. 8 and the deduced amino acid sequence is shown in FIG. 9 .
  • DNA sequence analysis revealed significant homology with human GALR3: approximately 95% protein sequence identity for 129 amino acids spanning TM4 through TM-7.
  • Northern blot analysis using a probe dervived from the rat GALR3 ORF has revealed expression of rat GALR3 mRNA in hypothalamus, mid-brain, pons, and whole fetal brain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US09/595,549 1997-12-17 2000-06-16 Nucleotide encoding human galanin receptor 3 (GALR3) Expired - Fee Related US6511827B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/595,549 US6511827B1 (en) 1997-12-17 2000-06-16 Nucleotide encoding human galanin receptor 3 (GALR3)
US10/212,980 US20030023074A1 (en) 1997-12-17 2002-08-06 Galanin receptor GALR3 and nucleotides encoding same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6972597P 1997-12-17 1997-12-17
PCT/US1998/026812 WO1999031130A1 (fr) 1997-12-17 1998-12-17 Recepteur galr3 de la galanine et nucleotides codant pour ce recepteur
US09/595,549 US6511827B1 (en) 1997-12-17 2000-06-16 Nucleotide encoding human galanin receptor 3 (GALR3)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026812 Continuation WO1999031130A1 (fr) 1997-12-17 1998-12-17 Recepteur galr3 de la galanine et nucleotides codant pour ce recepteur

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/212,980 Division US20030023074A1 (en) 1997-12-17 2002-08-06 Galanin receptor GALR3 and nucleotides encoding same

Publications (1)

Publication Number Publication Date
US6511827B1 true US6511827B1 (en) 2003-01-28

Family

ID=22090825

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/595,549 Expired - Fee Related US6511827B1 (en) 1997-12-17 2000-06-16 Nucleotide encoding human galanin receptor 3 (GALR3)
US10/212,980 Abandoned US20030023074A1 (en) 1997-12-17 2002-08-06 Galanin receptor GALR3 and nucleotides encoding same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/212,980 Abandoned US20030023074A1 (en) 1997-12-17 2002-08-06 Galanin receptor GALR3 and nucleotides encoding same

Country Status (5)

Country Link
US (2) US6511827B1 (fr)
EP (1) EP1037913A4 (fr)
JP (1) JP2002508169A (fr)
CA (1) CA2326694A1 (fr)
WO (1) WO1999031130A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092570A1 (en) * 2002-08-07 2004-05-13 Blackburn Thomas P. GAL3 antagonists for the treatment of neuropathic pain
US20060106089A1 (en) * 2004-10-21 2006-05-18 Mjalli Adnan M Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329197B2 (en) * 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
AU4420701A (en) * 2000-03-16 2001-09-24 Bayer Aktiengesellschaft Regulation of human galanin receptor-like g protein coupled receptor
KR101514440B1 (ko) * 2013-12-13 2015-04-22 고려대학교 산학협력단 갈라닌 수용체 3형의 리간드로서 스펙신의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015681A1 (fr) 1991-03-06 1992-09-17 Garvan Institute Of Medical Research GALANINE HUMAINE, DES CLONES ADNc CODANT POUR LA GALANINE HUMAINE ET PROCEDE DE PRODUCTION DE GALANINE HUMAINE
EP0711830A2 (fr) 1994-10-13 1996-05-15 Takeda Chemical Industries, Ltd. Récepteur de la galanine murin et humain
WO1997026853A2 (fr) 1996-01-24 1997-07-31 Synaptic Pharmaceutical Corporation Adn codant les recepteurs galr2 de la galanine et ses utilisations
WO1997046681A2 (fr) 1996-06-05 1997-12-11 Bayer Corporation RECEPTEUR DE LA GALANINE GalR2
EP0815570A1 (fr) * 1994-05-17 1998-01-07 Werner Dorsch Commutateur electrique actionnable mecaniquement
WO1998003548A1 (fr) 1996-07-19 1998-01-29 Astra Pharma Inc. Nouveau recepteur de galanine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329197B2 (en) * 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015681A1 (fr) 1991-03-06 1992-09-17 Garvan Institute Of Medical Research GALANINE HUMAINE, DES CLONES ADNc CODANT POUR LA GALANINE HUMAINE ET PROCEDE DE PRODUCTION DE GALANINE HUMAINE
EP0815570A1 (fr) * 1994-05-17 1998-01-07 Werner Dorsch Commutateur electrique actionnable mecaniquement
EP0711830A2 (fr) 1994-10-13 1996-05-15 Takeda Chemical Industries, Ltd. Récepteur de la galanine murin et humain
WO1997026853A2 (fr) 1996-01-24 1997-07-31 Synaptic Pharmaceutical Corporation Adn codant les recepteurs galr2 de la galanine et ses utilisations
WO1997046681A2 (fr) 1996-06-05 1997-12-11 Bayer Corporation RECEPTEUR DE LA GALANINE GalR2
WO1998003548A1 (fr) 1996-07-19 1998-01-29 Astra Pharma Inc. Nouveau recepteur de galanine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gen-Bank Accession No. Z97630, Oct. 29, 1997.
Habert-Ortoli, E. et al.; Molecular Cloning of a Functional Human Galanin Receptor; Proc. Natl. Acad. Sci. USA; vol. 91; pp. 9780-9783; 1994.
Sequence comparison to Gen-Bank Accession No. Z82241, Jan. 13, 1997.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092570A1 (en) * 2002-08-07 2004-05-13 Blackburn Thomas P. GAL3 antagonists for the treatment of neuropathic pain
US7220775B2 (en) 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain
US20060106089A1 (en) * 2004-10-21 2006-05-18 Mjalli Adnan M Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
US7582673B2 (en) 2004-10-21 2009-09-01 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
US20090247536A1 (en) * 2004-10-21 2009-10-01 Mjalli Adnan M M Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use

Also Published As

Publication number Publication date
CA2326694A1 (fr) 1999-06-24
WO1999031130A1 (fr) 1999-06-24
US20030023074A1 (en) 2003-01-30
EP1037913A4 (fr) 2002-11-20
JP2002508169A (ja) 2002-03-19
EP1037913A1 (fr) 2000-09-27

Similar Documents

Publication Publication Date Title
AU741041B2 (en) DNA encoding galanin GALR3 receptors and uses thereof
EP1019432A1 (fr) Recepteur ob et procedes de diagnostic et de traitement des dereglements de la masse corporelle
US6287855B1 (en) Nucleic acid encoding rat galanin receptor (GALR2)
WO1993004083A1 (fr) Compositions de canaux calciques humains et procedes
US6511827B1 (en) Nucleotide encoding human galanin receptor 3 (GALR3)
US6506877B1 (en) Ob receptor
US6337206B1 (en) Nucleic acid encoding mouse galanin receptor (GALR2)
US6949636B2 (en) Intron/exon structure of the human and mouse β3-adrenergic receptor genes
US20020137908A1 (en) Novel guanosine triphosphate (GTP) binding protein-coupled receptor protein, BG3
US6682908B1 (en) Mouse growth hormone secretagogue receptor
EP0600136B1 (fr) Structure de introns/exons de gènes codants pour les récepteurs bêta 3 adrénergiques souris et humain
AU782817B2 (en) Novel human G protein coupled receptor proteins and polynucleotides encoding the same
EP1311544B1 (fr) Nouvelles proteines humaines 7tm et polynucleotides codant pour ces proteines
US20020055626A1 (en) Novel human seven transmembrane proteins and polynucleotides encoding the same
US6635442B1 (en) Intron/exon structure of the human and mouse β3-adrenergic receptor genes
AU2006202575B2 (en) Novel seven transmembrane proteins and polynucleotides encoding the same
CA2420036A1 (fr) Proteines humaines 7tm et polynucleotides codant ces proteines
US20030225246A1 (en) Novel human 7TM proteins and polynucleotides encoding the same
US20070298489A1 (en) Novel human membrane proteins and polynucleotides encoding the same
CA2335272A1 (fr) Recepteur secretagogue d'hormones de croissance chez la souris

Legal Events

Date Code Title Description
AS Assignment

Owner name: VIRGINIA, UNIVERSITY OF, VIRGINIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LYNCH, KEVIN R.;REEL/FRAME:011376/0314

Effective date: 20001006

Owner name: MERCK & CO., INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOWARD, ANDREW D.;CASCIERI, MARGARET A.;SMITH, ROY G.;AND OTHERS;REEL/FRAME:011376/0337;SIGNING DATES FROM 20001004 TO 20001019

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:MERCK & CO., INC.;REEL/FRAME:023861/0293

Effective date: 20091102

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20150128

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载